Advertisement

Multiplexed Protein Signal Pathway Mapping Identifies Patients With Rectal Cancer That Responds to Neoadjuvant Treatment

      Abstract

      Background

      Currently there is no reliable technique for predicting clinical or pathologic complete tumor response after radiochemotherapy (RCT) in patients with rectal cancer. We applied reverse phase protein microarray (RPMA) technology to find a signal pathway that may predict the response to preoperative treatment.

      Patients and Methods

      Fifteen rectal cancer samples were collected during preoperative RCT. Seven patients had a good response to preoperative therapy (Mandard grade I-II) and 8 patients had a poor response (Mandard grade III-V). Using laser capture microdissection (LCM) and RPMA analysis, we measured the phosphorylation level of nearly 80 end points and analyzed the signaling pathways.

      Results

      We identified 4 signaling proteins whose phosphorylation levels were significantly different (P < .05) between the good vs. poor responders; CHK2 and β-catenin were more highly phosphorylated in poor responders, whereas PDK1 and glycogen synthase kinase (GSK)-3α/β had lower phosphorylation levels in poor responders. Interestingly GSK-3α/β, β-catenin, and PDK1 are all present in the phosphatidylinositol-3-kinase (PI3K)-AKT signaling pathway.

      Conclusions

      Based on our results, we hypothesize that the activating state of the PI3K-AKT pathway can stratify patients who could benefit most from neoadjuvant treatment. Moreover, identification of theranostic targets has the potential to pinpoint new therapeutic strategies for the nonresponsive population.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Phillips R.K.
        • Hittinger R.
        • Blesovsky L.
        • et al.
        Local recurrence following 'curative' surgery for large bowel cancer: I.
        Br J Surg. 1984; 71: 12-16
        • Minsky B.D.
        • Mies C.
        • Recht A.
        • et al.
        Resectable adenocarcinoma of the rectosigmoid and rectum.
        Cancer. 1988; 61: 1408-1416
        • Sauer R.
        • Becker H.
        • Hohenberger W.
        • et al.
        Preoperative versus postoperative chemoradiotherapy for rectal cancer.
        N Engl J Med. 2004; 351: 1731-1740
        • O'Neill B.D.
        • Brown G.
        • Heald R.J.
        • et al.
        Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer.
        Lancet Oncol. 2007; 8: 625-633
        • Gérard J.P.
        • Conroy T.
        • Bonnetain F.
        • et al.
        Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
        J Clin Oncol. 2006; 24: 4620-4625
        • Bosset J.F.
        • Collette L.
        • Calais G.
        • et al.
        Chemotherapy with preoperative radiotherapy in rectal cancer.
        N Engl J Med. 2006; 355: 1114-1123
        • Buie W.D.
        • MacLean A.R.
        • Attard J.A.
        • et al.
        Neoadjuvant chemoradiation increases the risk of pelvic sepsis after radical excision of rectal cancer.
        Dis Colon Rectum. 2005; 48: 1868-1874
        • Matthiessen P.
        • Hallböök O.
        • Andersson M.
        • et al.
        Risk factors for anastomotic leakage after anterior resection of the rectum.
        Colorectal Dis. 2004; 6: 462-469
        • Kuremsky J.G.
        • Tepper J.E.
        • McLeod H.L.
        Biomarkers for response to neoadjuvant chemoradiation for rectal cancer.
        Int J Radiat Oncol Biol Phys. 2009; 74: 673-688
        • Paweletz C.P.
        • Charboneau L.
        • Bichsel V.E.
        • et al.
        Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front.
        Oncogene. 2001; 20: 1981-1989
        • Petricoin E.F.
        • Bichsel V.E.
        • Calvert V.S.
        • et al.
        Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy.
        J Clin Oncol. 2005; 23: 3614-3621
        • Pierobon M.
        • Calvert V.
        • Belluco C.
        • et al.
        Multiplexed cell signaling analysis of metastatic and nonmetastatic colorectal cancer reveals COX2-EGFR signaling activation as a potential prognostic pathway biomarker.
        Clin Colorectal Cancer. 2009; 8: 110-117
        • VanMeter A.J.
        • Rodriguez A.S.
        • Bowman E.D.
        • et al.
        Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type.
        Proteomics. 2008; 7: 1902-1924
        • Wulfkuhle J.D.
        • Speer R.
        • Pierobon M.
        • et al.
        Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy.
        J Proteome Res. 2008; 7: 1508-1517
        • Mandard A.M.
        • Dalibard F.
        • Mandard J.C.
        • et al.
        Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma.
        Cancer. 1994; 73: 2680-2686
        • Jones S.
        • Zhang X.
        • Parsons D.W.
        • et al.
        Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
        Science. 2008; 321: 1801-1806
        • Parsons D.W.
        • Jones S.
        • Zhang X.
        • et al.
        An integrated genomic analysis of human glioblastoma multiforme.
        Science. 2008; 321: 1807-1812
        • Polakis P.
        Wnt signaling and cancer.
        Genes Dev. 2000; 14: 1837-1851
        • Peifer M.
        • Polakis P.
        Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus.
        Science. 2000; 287: 1606-1609
        • Korinek V.
        • Barker N.
        • Morin P.J.
        • et al.
        Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.
        Science. 1997; 275: 1784-1787
        • Morin P.J.
        • Sparks A.B.
        • Korinek V.
        • et al.
        Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC.
        Science. 1997; 275: 1787-1790
        • Pećina-Slaus N.
        Tumor suppressor gene E-cadherin and its role in normal and malignant cells.
        Cancer Cell Int. 2003; 3: 17
        • Clevers H.
        Wnt/beta-catenin signaling in development and disease.
        Cell. 2006; 127: 469-480
        • Albanese C.
        • Wu K.
        • D'Amico M.
        • et al.
        IKKalpha regulates mitogenic signaling through transcriptional induction of cyclin D1 via Tcf.
        Biol Cell. 2003; 14: 585-599
        • Agarwal A.
        • Das K.
        • Lerner N.
        • et al.
        The AKT/I kappa B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-kappa B and beta-catenin.
        Oncogene. 2005; 24: 1021-1031
        • Tan J.
        • Zhuang L.
        • Leong H.S.
        • et al.
        Pharmacologic modulation of glycogen synthase kinase-3beta promotes p53-dependent apoptosis through a direct Bax-mediated mitochondrial pathway in colorectal cancer cells.
        Cancer Res. 2005; 65: 9012-9020
        • Aschele C.
        • Cionini L.
        • Lonardi S.
        • et al.
        Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
        J Clin Oncol. 2011; 29: 2773-2780
        • Gérard J.P.
        • Azria D.
        • Gourgou-Bourgade S.
        • et al.
        Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.
        J Clin Oncol. 2010; 28: 1638-1644
        • Petricoin E.F.
        • Espina V.
        • Araujo R.P.
        • et al.
        Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival.
        Cancer Res. 2007; 67: 3431-3440